Objective To investigate the efficacy of pantoprazole and omeprazole as part of triple therapy in treatment of duodenal ulcer.
Methods Seventy-eight patients with duodenal ulcer and HP-positive were randomized to two groups. A random number table was used to generate random sequence. The sequence was not concealed. No blinding was used. Thirty-nine patients received pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 0.5 g (PAC group) and 39 patients received omeprazole 20 mg + amoxicillin 1.0 g + clarithromycin 0.5 g (OAC group), twice daily with duration of 7 days. The follow-up time was 4 to 6 weeks.
Results At the end of the treatment, 38 patients completed the study, and 1 patient lost to follow-up in the PAC group; thirty-seven patients completed the study, two patients lost to followup in the OAC group. The results of intention-to-treat analysis and per-protocol analysis showed that the HP eradication rates were 87.2%/89.5% in the PAC group and 87.2%/91.9% in the OAC group (P＞0.05); the clinical improvement rates were 79.4%/81.6% in the PAC group and 82.0%/86.5% in the OAC group (P＞0.05). The side effect rates were 10.6% in the PAC group and 8.1% in the OAC group (P＞0.05). No significant difference was found between the two groups (P＞0.05).
Conclusions The PAC group is therapeutically effective for eradication of HP and improves symptoms and has an equivalent effect to OAC group for patients with HP-positive duodenal ulcer. Both drugs are well tolerated.
Citation：
WANG Dan,HAN Shengxi. Clinical Trial of Efficacy of Triple Therapy of Pantoprazo le in Treatment of Duodenal Ulcer. Chinese Journal of Evidence-Based Medicine, 2005, 05(6): 444-447. doi:
Copy
Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved
| 1. |
杨雪松, 李益农. 溃疡病的胃镜下表现. 见李益农, 陆星华, 主编. 消化内镜学[M]. 第2版. 北京: 科学出版社, 2004. p. 359～363.
|
| 2. |
Yang XS, Li YN.Characteristics of peptic ulcer disease in endoscopy, see Li YN, Lu XH, chief editor: gastroenterologic endoscopy[M]. 2st edtion, Beijing: The Scientific Publishing Company. 2004. p. 359-363.
|
| 3. |
Futami H, Takashima M. Relationship between Helicobacter pylori infection and gastric metaplasia in the duodenal bulb in the pathogenesis of duodenal ulcer[J]. Gastroenterol Hepatol, 1999; 14(2): 114-119.
|
| 4. |
Kohda K, Tanaka K, Aiba Yasuda M,Miwa T, KogaY. Role of apoptosis induced by Helicobacter pylori infection in the development of duodenal ulcer[J]. Gut, 1999; 44(4): 456-462.
|
| 5. |
Tepes B, Kavcic B. A four-year follow-up of duodenal ulcer patients after Helicobacter pylori eradication[J]. Hepatogastroenterology, 1999; 46(27): 1746-1750.
|
| 6. |
Lind T, Megraud F, Unge P, Bayerdorffer E, OMOrain C, Spiller C. The MACH 2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies[J]. Gastroenterology, 1999; 116(2): 248-253.
|
| 7. |
Shin JM, Besancon M, Simon A. The site of action of Pantoprazole in the gastric H+/K+-ATPase[J]. Biochim Biophys Acta, 1993; 1148(2): 223-233.
|
| 8. |
Rehner M, Rohner HG, Schepp W. Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration, Amulticenter study[J]. Aliment Pharmacol Ther, 1995; 9(4): 411-416.
|
- 1. 杨雪松, 李益农. 溃疡病的胃镜下表现. 见李益农, 陆星华, 主编. 消化内镜学[M]. 第2版. 北京: 科学出版社, 2004. p. 359～363.
- 2. Yang XS, Li YN.Characteristics of peptic ulcer disease in endoscopy, see Li YN, Lu XH, chief editor: gastroenterologic endoscopy[M]. 2st edtion, Beijing: The Scientific Publishing Company. 2004. p. 359-363.
- 3. Futami H, Takashima M. Relationship between Helicobacter pylori infection and gastric metaplasia in the duodenal bulb in the pathogenesis of duodenal ulcer[J]. Gastroenterol Hepatol, 1999; 14(2): 114-119.
- 4. Kohda K, Tanaka K, Aiba Yasuda M,Miwa T, KogaY. Role of apoptosis induced by Helicobacter pylori infection in the development of duodenal ulcer[J]. Gut, 1999; 44(4): 456-462.
- 5. Tepes B, Kavcic B. A four-year follow-up of duodenal ulcer patients after Helicobacter pylori eradication[J]. Hepatogastroenterology, 1999; 46(27): 1746-1750.
- 6. Lind T, Megraud F, Unge P, Bayerdorffer E, OMOrain C, Spiller C. The MACH 2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies[J]. Gastroenterology, 1999; 116(2): 248-253.
- 7. Shin JM, Besancon M, Simon A. The site of action of Pantoprazole in the gastric H+/K+-ATPase[J]. Biochim Biophys Acta, 1993; 1148(2): 223-233.
- 8. Rehner M, Rohner HG, Schepp W. Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration, Amulticenter study[J]. Aliment Pharmacol Ther, 1995; 9(4): 411-416.
